Healius (ASX:HLS) Short Ratio


ASX:HLS Healius Ltd ASX:HLS
54 GF Score
Price A$0.38
GF Value A$1.01
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Healius Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ASX:HLS
54GF Score
Healius Ltd ASX:HLS
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Healius (ASX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, Healius stock appears to be undervalued. The current stock price of A$0.38 is trading 62.4% below its estimated GF Value™ of A$1.01. GuruFocus considers Healius to be Possible Value Trap.

Key valuation signals for ASX:HLS:

  • Short Ratio:
  • GF Value™: A$1.01 vs. price of A$0.38 (62.4% below fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the ASX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healius Business Description

Other Exchanges PGZ:Germany
Address 161 Castlereagh Street, Level 22, Sydney, NSW, AUS, 2000
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
54GF Score

Get the complete analysis for ASX:HLS

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.38
Price
A$1.01
GF Value